A New FDA-approved Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis in Adults Sponsored by Precigen, Inc

Recurrent respiratory papillomatosis (RRP) is a rare, chronic disease primarily caused by human papillomavirus (HPV) 6 and HPV11. In this presentation, we will discuss pivotal trial data for a new, FDA-approved, non-surgical treatment option that targets the root cause of RRP.